Abcam PLC (ABCM)
|Net Income (ttm)||15.82M|
|Trading Day||January 25|
|Day's Range||23.19 - 23.90|
|52-Week Range||18.20 - 23.90|
Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following releas...
CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consul...
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex as... [Read more...]
|IPO Date |
Oct 22, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, Abcam PLC's revenue was 260.00 million, an increase of 0.04% compared to the previous year's 259.90 million. Earnings were 12.50 million, a decrease of -72.22%.
According to 2 analysts, the average rating for Abcam PLC stock is "Buy." The 12-month stock price forecast is 1,562.54, which is an increase of 6,440.56% from the latest price.